EmicizumabMeSH Supplementary Concept

https://ansm.sante.fr/tableau-marr/emicizumab
2024
false
false
false
France
French
emicizumab
risk management
thromboembolism
hemorrhage
thrombotic microangiopathies
blood coagulation tests
risk
hemorrhage
hemophilia A
patients guideline
guidelines for drug use
handbooks
Drug-Related side effects and adverse reactions
injections, subcutaneous
emicizumab
emicizumab
continuity of patient care
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3443949/fr/hemlibra-emicizumab-hemophilie-a
2023
false
false
false
France
emicizumab
treatment outcome
insurance, health, reimbursement
hemorrhage
guidelines for drug use
evaluation of the transparency committee
hemophilia A
emicizumab

---
https://www.has-sante.fr/jcms/p_3447364/fr/hemlibra-emicizumab-hemophilie-a-deficit-congenital-en-facteur-viii
2023
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
emicizumab
hemophilia A
hemorrhage
emicizumab
evaluation of the transparency committee

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/reevaluation-dhemlibramc-emicizumab-hemophilie-de-type-a-sans-inhibiteur-mise-a-jour-de-la-liste-des-produits-du-systeme-du-sang-du-quebec-mars-2021.html
2021
false
false
false
Canada
drug evaluation
emicizumab
hemophilia, nos
Hemophilia
waiting lists
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3124681/fr/hemlibra
2019
false
false
false
France
insurance, health, reimbursement
treatment outcome
emicizumab
emicizumab
hemophilia A
hemorrhage
injections, subcutaneous
evaluation of the transparency committee
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3120946/fr/hemlibra
2019
false
false
false
France
emicizumab
emicizumab
insurance, health, reimbursement
treatment outcome
hemophilia A
hemorrhage
evaluation of the transparency committee
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://sfar.org/prise-en-charge-personne-hemophile-a-avec-inhibiteur-traitee-par-emicizumab-dans-contexte-chirurgie-ou-hemorragie/
2019
false
false
false
France
hemophilia A
surgical procedures, operative
blood loss, surgical
postoperative hemorrhage
injections, subcutaneous
hemorrhage
recombinant FVIIa
anti-inhibitor coagulant complex
tranexamic acid
algorithms
F8 protein, human
practice guideline
hemorrhage
patient care management
emicizumab
antibodies, bispecific
antibodies, monoclonal, humanized
factor VIIa
recombinant proteins
blood coagulation factors
factor VIII

---
https://www.has-sante.fr/portail/jcms/c_2868847/fr/hemlibra
https://www.has-sante.fr/portail/jcms/c_2868847/fr/hemlibra-emicizumab-hemostatique
2019
false
false
false
France
French
treatment outcome
emicizumab
hemophilia A
hemorrhage
hemorrhage
Factor VIII antibody (substance)
injections, subcutaneous
adult
child
aged
evaluation of the transparency committee
guidelines for drug use
hemostatics
emicizumab
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3114482/fr/hemlibra
2019
false
false
false
France
emicizumab
emicizumab
injections, subcutaneous
hemorrhage
hemophilia A
adult
adolescent
treatment outcome
insurance, health, reimbursement
child
evaluation of the transparency committee
antibodies, bispecific
antibodies, monoclonal, humanized

---
https://www.ema.europa.eu/medicines/human/EPAR/Hemlibra
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
emicizumab
drug approval
europe
treatment outcome
emicizumab
hemophilia A
hemorrhage
hemorrhage
Factor VIII antibody (substance)
injections, subcutaneous
product surveillance, postmarketing
adult
child
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
emicizumab
antibodies, bispecific
antibodies, monoclonal, humanized
antibodies, bispecific
antibodies, monoclonal, humanized

---